-
Most Popular
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
New Drug Could Cut ‘Bad’ Cholesterol Nearly in Half
Late stage trials of Alirocumab, an anti-cholesterol drug from Regeneron and Sanofi, showed promising results.
Don’t Bet Against Biotech in 2013 … or Ever
Betting against biotech is usually a dangerous game for retail investors -- add leverage and you're entering Crazytown.
Flu Season Is Coming — And These Companies Are Ready
Flu season is slowly getting started -- bad news for us, but welcome news for companies that benefit from flu sufferers' ills. Here's a look at some of them.
Biotech Blowout: 3 Stocks Taking a Hit
The risky side of biotech stocks reared its ugly head in the past couple of days, sending three stocks to the mat in the wake of bad news.
Should I Buy GlaxoSmithKline (GSK)? 3 Pros, 3 Cons
GlaxoSmithKline is seeking approval for the world's first malaria vaccine, but high debt and low growth mean investors should think twice before buying.
Look to Supplier Stocks for an Obamacare Trade
Wall Street hasn't paid much attention to Questcor (QCOR), a drug company with patients that could be moving to Medicaid in droves.
Roche’s Breast Cancer Drug Approval Is Just the Beginning
It might have been dismissed as irrelevant by most investors, but Roche and its Perjeta could reshape the breast cancer drug landscape.
5 Stocks Leading the Generic Drug Charge
As pervasive as generic drug usage has already become, experts say there's still lots of room to grow. These companies are leading that charge.
Bull’s Eye Report: Parexel (PRXL)
Parexel is one of the best opportunities in pharma right now.
Trade of the Day: Cytokinetics (CYTK)
Though this pharmaceutical stock has been battered lately, both analysts and management are confident in the company's drug currently in the FDA pipeline.
3 Pharma Stocks Just Running in Place
Gobs of free cash flow doesn't mean a company is worth buying. Some companies, especially pharmaceuticals, just use cash to run in place.
This Top Sector Should Continue to Outperform
iShares Nasdaq Biotechnology (IBB) is trading within a powerful bull channel and just flashed a new buy signal.
The One Word You Should Know in Biopharma Right Now
Before you become impressed with a particular biopharma company's drug, you'll want to know this detail.
Biopharma’s 6 Biggest Deals: Were They Worth It?
With Amgen set to spend more than $10 billion to buy Onyx, investors are wondering if these super-sized biopharma acquisitions are worth it.
How to Profit From Every Biotech Buyout
Amgen's acquisition of Onyx underscores the fact that one simple biotech investment may also be the best one.
Grab These 3 Short-Term ETF Bargains While They Last
Leadership in the ETF circles has been focused on the regional and larger banks, gold miners, Internet, biotech and restaurant funds.
Will MannKind’s Luck Change the Second Time Around?
MannKind's diabetes drug, Afrezza, is back in Phase 3 trials and is showing similar promise. But can it clear the hump to approval ... unlike last time?
Pfizer & Merck: Dividend Winners or Duds?
Pfizer and Merck got addicted to Lipitor and Singulair, and now slumping sales of the former blockbusters have both companies scrambling for growth.
3 Perfect Biopharma Picks for Your Portfolio
If you want to play the volatile biopharma arena, choose carefully. Here are three hot stocks in the sector for different risk tolerances and time horizons.
